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Clinical Benefit and Long-Term Outcome
After Intracoronary Autologous Bone Marrow Cell
Transplantation in Patients With Acute Myocardial Infarction
Muhammad Yousef, MD, Christiana Mira Schannwell, MD, Mathias Köstering, MD,
Tobias Zeus, MD, Michael Brehm, MD, Bodo Eckehard Strauer, MD
Düsseldorf, Germany
Objectives The aim of this study was to investigate the quantitative amount of improvement of ventricular hemodynamic
status, geometry, and contractility as well as the long-term clinical outcome of cell-treated patients after acute
myocardial infarction (AMI).
Background Animal experiments as well as clinical studies have demonstrated that autologous bone marrow cell (BMC)
transplantation might improve ventricular function and prevent remodeling.
Methods Sixty-two patients underwent intracoronary autologous BMC transplantation 7  2 days after AMI. Cells were
infused directly into the infarct-related artery. The control group consisted of 62 patients with comparable left
ventricular (LV) ejection fraction (EF) and diagnosis. All patients had several examinations (e.g., coronary angiog-
raphy, right heart catheterization, biplane left ventriculography, electrocardiogram [ECG] at rest and exercise,
echocardiography, late potential [LP], heart rate variability [HRV], and 24-h Holter ECG). The therapeutic
follow-up was performed 3, 12, and 60 months after BMC therapy.
Results Three months after BMC therapy there was significant improvement of EF and stroke volume index. The infarct
size was significantly reduced by 8%. Contraction velocities (lengths/second, volumes/second) increased signifi-
cantly and the slope of the ventricular function curve (systolic pressure/end-systolic volume) became steeper.
There was significant improvement of contractility in the infarct zone, as evidenced by a 31% increase of LV ve-
locity of shortening (VCF), preferably in the border zone of the infarct zone. In contrast, the noninfarcted area
showed no difference in VCF before and after BMC therapy. Furthermore, decreases of abnormal HRV, LP, and
ectopic beats were documented after BMC therapy. Twelve and 60 months after BMC therapy the parameters of
contractility, hemodynamic status, and geometry of the LV were stable. The exercise capacity of treated patients
was significantly augmented, and the mortality was significantly reduced in comparison with the control group.
Conclusions BMC therapy leads to significant and longstanding improvements of LV performance as well as quality of life
and mortality of patients after AMI. After BMC therapy, no side effects were observed, showing that BMC therapy
is safe. (J Am Coll Cardiol 2009;53:2262–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.051i
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cfter acute myocardial infarction (AMI), a variety of
tructural and histopathological changes occur in the left
entricular (LV) myocardium (remodeling) that lead to
rogressive decline in LV performance. The infarcted area is
nable to resist the pressure and volume load on the heart in
he same manner as the healthy tissue. Consequently, there
s dilatation of the chamber arising from the infarct region.
entricular mass and volume increase, which together
dversely affect cardiac function.
rom the Department of Medicine, Division of Cardiology, Pneumology and
ngiology, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany.m
Manuscript received November 14, 2008; revised manuscript received February 18,
009, accepted February 23, 2009.Medical treatment or revascularization after AMI can
mprove the function of viable or hibernating myocardium,
ut cannot restore necrotic myocardial tissue. Current ther-
py strategies are limited in the prevention and reversal of
emodeling of the LV after AMI. Therefore, development
f new therapy options is desirable to decrease the incidence
f heart failure and to prevent and reverse the remodeling
rocess after AMI.
See page 2270
Several animal experiments (1–3) and, more recently,
linical studies (4–16) have shown that autologous bone
arrow cell (BMC) transplantation might improve ventric-
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June 16, 2009:2262–9 The BALANCE Studylar function and prevent remodeling, when given directly
nto the infarct-related coronary artery system.
The aim of this study was to investigate the quantitative
mount of improvement of ventricular hemodynamic status,
eometry, and contractility as well as to explore the long-
erm (5 years) clinical outcome of treated patients after
MI.
ethods
tudy population. A total of 124 patients with AMI were
nrolled into the present study. All patients underwent emer-
ency coronary angiography 10  9 h after the onset of the
MI. The infarct-related artery was recanalized by balloon
ngioplasty and/or stent implantation. Sixty-two patients un-
erwent intracoronary BMC transplantation 7  2 days after
he onset of AMI (BMC group). The control group consisted
f 62 patients with comparable ejection fraction (EF) and
iagnosis. General exclusion criteria were alcohol or drug
ependency; acute myocarditis; human immunodeficiency,
epatitis B, or hepatitis C virus infections; pregnancy; and
vidence for malignant and hematologic diseases. All patients
ere treated with aspirin, clopidogrel, beta-blocker,
ngiotensin-converting enzyme inhibitor (AT2-receptor an-
agonist), and a diuretic agent (Table 1).
tudy design. In 2002 to 2003, the novel kind of BMC
herapy was proposed for all patients with AMI 7  2 days
fter revascularization. Patients that refused the BMC treat-
Baseline Characteristics of BMC and Control Gr
Table 1 Baseline Characteristics of BMC an
Characteristics
Age (yrs)
BMI (kg/m2)
Sex (% male)
CKmax (U/l) 1
EF (%)
Infarct-related RCA/LAD/RCX (%) 32
Patients with unplanned hospital stay (%)
Patients with repeat PCI (%)
Number of injected cells (107)
Number of diseased coronary arteries
Medications (%)
Aspirin
Clopidogrel
ACE-I/angiotensin-II receptor blocker
Statins
Beta-blocker
Cardiovascular risk factors (%)
Diabetes mellitus
Hyperlipidemia
Smoking
Obesity
Arterial hypertension
Sixty-two patients were treated with bonemarrow cells (BMCs). The con
creatine kinase (CKmax); diagnosis; body mass index (BMI); and numb
Values are mean  SD or %.ACE-I  angiotensin-converting enzyme inhibitor; LAD  left anterior des
RCA  right coronary artery; RCX  right circumflex coronary artery.ent and agreed to undergo all
rocedures identical to the BMC
roup acted as the control group.
ll patients underwent coronary
ngiography, biplane left ventricu-
ography, right heart catheteriza-
ion, echocardiography, dobut-
mine stress echocardiography,
ate potential (LP), short-term
eart rate variability (HRV), elec-
rocardiogram (ECG) at rest, and
4-h Holter ECG. The therapeu-
ic follow-up was performed 3, 12,
nd 60 months after the treatment
Fig. 1). The present study was
pproved by the ethic commission
f Heinrich-Heine-University of
uesseldorf, Germany.
reparation of BMCs. Bone
arrow was taken (80 to 120 ml
rom the iliac crest), and mononuclear cells—including
D34, CD133, and CD34 cells—were isolated and
dentified according to the Paul-Ehrlich criteria under
ood Manufacturing Practice. Cells were isolated by Ficoll
ensity separation on Lymphocyte Separation Medium (Bio
hittaker, Walkersville, Maryland), before the residual
rythrocytes were lysed with water. The BMCs were washed
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMC  bone marrow cell
ECG  electrocardiogram
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
HRV  heart rate variability
LP  late potential
LV  left ventricle/
ventricular
SVI  stroke volume index
VCF  velocity of
circumferential fiber
shortening
ntrol Group
roup
62)
Control Group
(n  62) p Value
10.8 50.7 8.3 NS
3.7 27 36 NS
.1 92 NS
998 1,151 919 NS
10.6 57.2 10.4 NS
.8/18.6 28/52/20 NS
.52 12.9 NS
.06 9.68 NS
3.9 —
0.69 1.6 0.71 NS
100 NS
100 NS
94 NS
91 NS
92 NS
5 NS
91 NS
54 NS
57 NS
49 NS
up consists of 62 patients with comparable ejection fraction (EF); peak
seased coronary arteries, medication, and cardiovascular risk factors.cending coronary artery; PCI  percutaneous coronary inoup
d Co
BMC G
(n 
51.4
26.9
87
,131
51.6
.6/48
14
8
6.1
1.61
100
100
95
90
93
6
94
52
60
52
trol gro
er of ditervention;
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The BALANCE Study June 16, 2009:2262–9times with heparinized saline. Viability was 93  3%. All
icrobiologic tests of clinically used cell preparations proved
egative.
pplications of BMCs. Cells were infused directly into
he infarct-related artery via an angioplasty balloon catheter,
hich was located within the previously stented coronary
egment and inflated at a low pressure. The cell transplan-
ation was performed via 4 fractional infusions parallel to
alloon inflation over 4 min. Percutaneous transluminal
oronary angioplasty (PTCA) thoroughly prevented the
ackflow of cells and at the same time produced a stop-flow
eyond the site of the balloon inflation to facilitate high-
ressure infusion of cells into the infarcted zone. Thus,
rolonged contact time for cellular migration was allowed
17). To achieve a maximal ischemic stimulus, all patients
eceived dobutamine intravenously and dipyridamol by intra-
oronary application (18). To ensure a prolonged contact time
or cellular adhesion of the mononuclear cells, we additionally
pplied intracoronary macroalbumin aggregates (19).
unctional assessment of hemodynamic status. Infarct
ize, EF, regional wall movement, and wall stress of the
nfarcted zone during ejection were determined by quanti-
ative left ventriculography (Quantcor, version 4.0, Siemens,
rlangen, Germany) that was obtained before coronary
ngiography (Judkins technique) by intraventricular injec-
ion of 20 to 40 ml Ultravist (Bayer Schering Pharma,
erlin, Germany). For each ventriculogram a specific en-
argement and aberration factor was taken into account for
valuation and calculation of volumes. The infarct size was
alculated according to the method of Sheehan (20). The
V regional function, wall thickness, wall thickness
Figure 1 Study Design
Sixty-two patients underwent intracoronary bone marrow cell (BMC) transplanta-
tion 7  2 days after the onset of acute myocardial infarction (AMI) (BMC
group). The control group consisted of 62 patients with comparable ejection
fraction and diagnosis. All patients underwent several examinations. The thera-
peutic follow-up was performed 3, 12, and 60 months after the treatment.
ECG  electrocardiogram.hanges, and wall stress were determined in 3 to 4 ventric- dlar wall segments. Perpendicular to the LV longitudinal
xis (connecting line between the middle of the aortic valve
nd the ventricular apex), 3 to 4 vertical axes were estab-
ished at equal distances (approximately 0.5 cm), and the
nterior hemiaxes were drawn. A tangent was drawn to the
xternal ventricular contour in such a way that its perpen-
icular passed through the intersecting point of the hemi-
xis and the interior ventricular contour, thus obtaining
entricular wall segments and distances of approximately
entrifugal shape, when seen from a virtual ventricular
enter. This technique was chosen because, in contrast to
ther techniques, it helps to prevent or reduce potential
verratings of the regional wall thickness, particularly in the
asal and apical segments, which otherwise might occur due
o distortions in the projection of the outer ventricular
ontour.
The contractility index LV systolic pressure (Psyst)/end-
ystolic volume (ESV) was calculated by dividing Psyst by
SV, the velocity of shortening (VCF) as the ratio of
hortening/ejection time (mm/s) and the mean normal-
zed systolic ejection rate as the ratio of EF/ejection time
volume/s). An identical methodological procedure was
erformed for both stem cell and control group patients.
ssessment of arrhythmia. For risk stratification LP,
RV, and 24-h Holter ECG were analyzed. The results of
4-h Holter ECG were listed according to the Lown
lassification.
tatistical analysis. All data are presented as mean 
D. Intraindividual comparison of continuous variables
t baseline with those at follow-up was performed with
he paired t test. Comparison of nonparametric data
etween groups was performed with the Wilcoxon rank
um test and the Mann-Whitney U test. Nonparametric
orrelation was calculated by the Spearman correlation.
tatistical significance was assumed at a value of p 
.05. For comparisons of various post-treatment evalua-
ions versus baseline (Table 2), Bonferroni alpha correc-
ion was performed and statistical significance was as-
umed at a value of p  0.0167. Time-dependent
ortality rates were estimated by Kaplan-Meier survival
urves, and p values were determined by use of log-rank
tatistics. All statistical analyses were performed with
PSS for windows (version 15, SPSS, Chicago, Illinois).
esults
aseline characteristics. Clinical data within BMC group
nd control group did not differ significantly (Table 1). The
reatine kinase activity was almost the same, and the initial
F was quantitatively similar. The average of transplanted
MCs in treated patients was 6.1  3.9  107 cells. In the
ourse of this long-term study the number of patients that
eceived repeat percutaneous coronary intervention and the
umber of patients with an unplanned hospital stay did not
iffer significantly between the BMC and the control group.
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June 16, 2009:2262–9 The BALANCE Studyo differences for pharmacological treatment and cardio-
ascular risk factors were present (Table 1).
uantitative ventriculography. Three months after intra-
oronary BMC transplantation, considerable improvements
n the LV performance were observed. The EF improved
ignificantly by 7.9% (p  0.01), and the stroke volume
ndex (SVI) at rest increased by 16.5%. Furthermore, there
as a significant decrease in both end-diastolic volume
EDV) and ESV (Table 2). The infarct size was consider-
bly reduced, by 8% (Table 3, Fig. 2). No significant
orrelation has been documented between the number of
njected cells and the infarct size reduction (p  0.406) or
he EF improvement (p  0.426).
ontractility of the LV. The LV contractility was deter-
ined by several indexes. Contraction velocities (length/s,
olume/s) increased, and the contractility index (Psyst/ESV)
uantitative Ventriculography Before and 3, 12, and 60 Months Af
Table 2 Quantitative Ventriculography Before and 3, 12, and 6
Parameter
BMC Group
Baseline
(Before BMC Therapy)
After 3
Months
After 12
Months
EDV (ml)
Mean 150 28 147 29 146 26
Abs. — 2.7 18.3 3.9 18
ESV (ml)
Mean 73.4 26 60.8 25* 61.1 20*
Abs. — 12.6 10.3 12.4 11.1
EF (%)
Mean 51.6 11 59.5 12* 58.3 11*
Abs. — 7.9 6.9 6.9 7.7
SVI (ml/m2)
Mean 38.9 10 45.2 11* 43.6 11†
Abs. — 5.45 10.8 4.7 8.7
alues are mean SD. Quantitative ventriculography over the course of time after acute myocardi
lpha correction); †p  0.05 versus baseline.
Abs.  absolute difference to baseline; EDV  end-diastolic volume; EF  ejection fraction; ESV
nfarct Size and LV Contractility
Table 3 Infarct Size and LV Contractility
Parameter
AMI
BMC Group Control Group
MNSER (vol/s)
Baseline 1.78 0.69 1.8 0.71
After BMC therapy 1.98 0.77* 1.83 0.76
Abs. 1.6 1.5 0.32 0.9
Psyst/ESV (mm Hg/s)
Baseline 1.96 0.82 2.1 0.71
After BMC therapy 2.6 1.2* 2.3 0.81
Abs. 0.65 0.66 0.13 0.33
Infarct size (%)
Baseline 22 15.4 26 9.4
After BMC therapy 14 11.5* 21 9.1
Abs. 8.2 9 5.3 12.9
nfarct size and left ventricular (LV) contractility parameters before and after BMC therapy. *p 
.01 (pre/post).
MNSER  mean normalized systolic ejection rate; Psyst/ESV  contractility index calculated by
ividing LV systolic pressure (Psyst) by ESV; other abbreviations as in Table 2.mproved significantly (Table 3). The absolute difference in
syst/ESV differed significantly between the 2 patients
roups. Over the infarcted region, VCF increased signifi-
antly by 31% and the end-systolic wall stress decreased by
.6% in the BMC group (Table 4).
rrhythmogenic indexes. In treated patients decreases of
bnormal HRV, LP, and ectopic beats were observed
Table 5).
esults 12 and 60 months after cell therapy. After 12 and
0 months deterioration of LV performance occurred in the
ontrol group as evidenced by increases in EDV and ESV as
ell as by decreases in EF (Fig. 3) and SVI (Table 2). In
ontrast, BMC-treated patients after the initial improve-
ent of ventricular function maintained the improved level
MC Therapy in Comparison With the Control Group
nths After BMC Therapy in Comparison With the Control Group
AMI
Control Group
fter 60
Months Baseline
After 3
Months
After 12
Months
After 60
Months
47 19 157 19 153 17 160 17 164 21
.2 17.7 — 3 10 4.9 14.5 11.6 20.2
.6 18 78.2 25 73.4 20 81.7 24 88.4 24†
.6 13.5 — 3.1 7.7 6.2 9.7 15.9 14.9
.9 9† 50.8 10 52.4 9 49.5 9.3 46.9 8.3†
.6 6.6 — 1 1.98 2.3 2.7 5.8 4
43 8 38.2 10 39 9 37.6 9 36.5 8
.4 6.5 — 0.35 1.84 1.24 3.5 6.7 13.9
tion (AMI) in bone marrow cell (BMC) and control group. *p 0.0167 versus baseline (Bonferroni
-systolic volume; SVI  stroke volume index.
Figure 2 Infarct Size Before and After
BMC Therapy in Patients With AMI
Infarct size was significantly reduced in the bone marrow cell (BMC)
group. AMI  acute myocardial infarction; STX  stem cell transplantation.ter B
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The BALANCE Study June 16, 2009:2262–9f performance even after 5 years. Thus, the time course of
MC treatment is characterized by an initial peak improve-
ent (3 months) and an antiremodeling effect (12 and 60
onths, respectively) associated with preservation of LV
unction over time. The absolute difference between base-
ine and at 3-month follow-up in ESV and EF differed
ignificantly between the BMC and control group.
ortality. Mortality of BMC-treated patients was signif-
cantly reduced in comparison with the control group (all
eaths were cardiac deaths). Within a median follow-up
ime of 4.6  2.1 years in the BMC group, 1 patient died,
nd of 4.8  2.2 years in the control group, 7 patients died.
hese numbers are equivalent to average mortality rates of
.35%/year in the BMC group and of 2.35%/year in the
ontrol group (p  0.03). Accordingly, steepness of calcu-
ated mortality curves was thoroughly different in treated
atients versus control subjects, demonstrating, in terms of
egional Ventricular Function
Table 4 Regional Ventricular Function
Parameter
BMC Gro
Infarcted
T-end-systolic (103  N  m2)
Baseline 29.2 15.7
After BMC therapy 26.7 14.5*
Abs. 2.4 7.9
T-end-diastolic (103  N  m2)
Baseline 5.3 2.5
After BMC therapy 5 2.8
Abs. 0.25 2.7
VCF (mm/s)
Baseline 15.9 16.8
After BMC therapy 20.9 16.6*
Abs. 4.9 11.8
mprovements of T-end-systolic and wall movement velocity (VCF) were observed 3 months after B
T-systolic) in the LV infarcted area in comparison with the noninfarcted area in the BMC and con
Abbreviations as in Table 2.
rrhythmogenic Indexes
Table 5 Arrhythmogenic Indexes
Parameter
AMI
BMC Group Control Group
LP: (no. of Simson criteria)
Baseline 1.67 1.14 1.45 0.98
After BMC therapy 1.56 1.15 1.5 1.02
Abs. 0.11 0.76 0.5 0.77
HRV: SD of the RR-intervals (ms)
Baseline 34 17.5 37 15.2
After BMC therapy 48.2 18.8* 33.1 14.2
Abs. 14.2 24.2 3.5 8.3
Lown class
Baseline 1.56 1.5 1.43 1.8
After BMC therapy 0.76 0.6* 1.92 1.2
Abs. 0.8 1.5 0.48 1
rrhythmogenic indexes before and after BMC therapy. Improvements of late potential (LP), heart
ate variability (HRV), and Lown class were observed. *p  0.05 (pre/post).
Abbreviations as in Table 2.aplan Meier repression analysis, reduced mortality rates in
he treated patient group (Fig. 4).
iscussion
he BALANCE (Clinical Benefit and Long-Term Out-
ome After Intracoronary Autologous Bone Marrow Cell
ransplantation in Patients With Acute Myocardial Infarc-
ion) study represents the longest available clinical follow-up
rial after intracoronary BMC therapy in patients with
MI. The results of the present study are comparable to the
linical outcome data of prior trials (5–16) and meta-
AMI
Control Group
Noninfarcted Infarcted Noninfarcted
8.7 3.5 28.6 14.9 8.3 3.7
9 3.6 29.9 15.4 9.8 4.1
0.35 1.6 1.3 8.3 0.8 2.1
3.8 1.5 5.2 2.4 3.7 1.6
3.7 1.6 5.2 2.9 3.8 1.8
0.12 1.7 0.5 1.2 0.15 1.3
47.9 23.3 15.9 14 48.3 24
46.3 17.3 15.2 14.2 49.2 23
1.7 19.4 0.7 10.5 0.8 16.3
nsplantation in the infarcted area. The VCF, end-diastolic (T-diastolic), and end-systolic wall stress
ps. *p  0.05 (pre/post).
Figure 3 EF Over the Course of Time After BMC Therapy in
Patients With AMI in Comparison With the Control Group
Ejection fraction (EF) improves significantly in the bone marrow cell (BMC)
group. The initial beneficial effect of BMC therapy, as evidenced by a signifi-
cant improvement of EF after 3 months, was longstanding after 12 and 60
months. In contrast, the EF decreases in the control group. AMI  acute myo-
cardial infarction.up
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June 16, 2009:2262–9 The BALANCE Studynalyses (21–23) employing stem cell therapy after AMI,
emonstrating that in infarcted myocardium BMC therapy
mproves LV hemodynamic (SVI, EF, and the like) (Table 2),
V contractility indexes (VCF [length/s, volume/s]), Psyst/
SV (Tables 3 and 4), and LV geometry (decrease in EDV
nd ESV, decrease in infarct size) (Tables 2 and 3). The
ontractile behavior of the infarcted myocardium was sig-
ificantly ameliorated in comparison with the noninfarcted
yocardium (Table 4). Moreover, intracoronary BMC
herapy also was associated with other beneficial effects,
uch as improvement of LP and HRV (Table 5). Another
mportant result refers to the considerable decrease in
ortality of treated patients over a median follow-up time
f 4.6  2.1 years (Fig. 4).
deal time point of BMC application. In the present
tudy, the time point of BMC transplantation was 7  2
ays after the onset of the AMI, because the infarct-related
nflammatory process is strongest in the first 5 days after
MI and, therefore, immediate BMC transplantation is not
dvisable (24). However, 2 weeks after AMI, beginning scar
ormation might reduce the beneficial effects of BMCs
25,26). Therefore, the ideal time point for BMC trans-
lantation is most likely between 5 and 14 days after the
nset of AMI.
egional LV function. When analyzing regional LV func-
ion, the contractile improvement was predominant within
he infarcted area, whereas the noninfarcted muscle was
lmost unchanged. Regional VCF increased significantly by
1% within the infarcted area, whereas the noninfarcted
rea was unaffected. This result might underline the impor-
ance of the border zone for BMC-associated repair of the
nfarcted myocardium, because regeneration of blood vessels
nd muscle cells is most pronounced in the border zone of
Figure 4 Mortality in Patients With AMI After BMC
Therapy in Comparison With the Control Group
The mortality of the bone marrow cell (BMC) group was significantly reduced
in comparison with the control group. AMI  acute myocardial infarction.nfarcted tissue. cThis considerable increase in VCF reflects a BMC-
elated increase in contractility within the infarct zone
nd/or the border zone. Changes of VCF are not only due
o changes in contractility but also, in part, to altered load
actors of the heart (preload, afterload). However, VCF
elated to systolic wall stress (i.e., to the force/cross-
ectional area of the LV wall) shows that, per given systolic
all stress, the VCF is increased after BMC therapy. This
mplies that the formerly (before BMC therapy) avital and
ow or noncontractile tissue has regenerated contractile
roperties again, by regeneration of new myocytes or by
ontractile improvement of diseased myocytes within the
order zone or by both. The noninfarcted myocardial tissue
as unchanged with regard to VCF and systolic stress,
ndicating again the importance of the border zone for
egeneration of infarcted myocardium.
MC effects versus spontaneous healing and remodeling.
he persistent beneficial effects over the follow-up time
ustify the assumption that BMC treatment might overcome
he possibly detrimental effects of ventricular remodeling.
emodeling after myocardial infarction represents a major
ause of infarct-related heart failure and death. This process
epends on acute and chronic transformation of both the
ecrotic infarct region and the non-necrotic, peri-infarct
issue (27). Remodeling is difficult to quantify; however, it
ccurs in approximately 60% of cardiac patients after myo-
ardial infarction (28).
The infarct size is a major determinant of ventricular
emodeling and determines the likelihood of late remodel-
ng after myocardial infarction (29). Several studies have
emonstrated a benefit from myocardial reperfusion by an
pened infarct-related artery, resulting in reduced infarct
ize and in improvement of late regional and global ventric-
lar function (30,31). The present study demonstrates that
eduction of infarct size is associated with an improvement
n LV function. The values (e.g., LVEF, infarct size) of
ontrol patients, although nonsignificant, might reflect a
ertain spontaneous healing. In contrast, the BMC group
xhibits a considerable and highly significant decrease in
nfarct size, which also goes parallel to the improved LV
erformance (LVEF). Thus, even when taking a certain
mount of spontaneous healing—as in AMI—into account,
here is enough evidence for beneficial BMC-related effects
hat become manifest in addition to the conventional
herapeutic procedure. In contrast, the apersistent beneficial
ffects over the long follow-up time justify the assumption
hat BMC treatment might overcome the possibly detri-
ental effects of ventricular remodeling.
ortality after intracoronary BMC transplantation. The
resent study demonstrated considerable and significant
eduction of mortality in the BMC group in comparison
ith the control group (p  0.03).
Other factors (e.g., repeat PTCA, stent implantation,
ortocoronary venous bypass) that might influence clinical
enefit or mortality after a new treatment have to be
onsidered. However, the percentage of repeat PTCA and
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The BALANCE Study June 16, 2009:2262–9f aortocoronary venous bypass was not different between
he BMC and the control group, demonstrating that these
on–BMC-related procedures most probably do not inter-
ere with the beneficial results obtained by BMC treatment.
Furthermore, when comparing the mortality rates from
his study with mortality rates of other studies containing
omparable diagnoses and equivalent hemodynamic status,
t becomes evident that mortality of 1.6% 5 years after AMI
as not been reported until now in the published reports
hat analyze long-term mortality or survival in patients with
MI (mortality 13% to 24% after 5 years) (32).
The reason for long-term survival in the BMC group
ight be due primarily to a decrease of 2 of the main reasons
or deaths in patients with coronary artery disease (i.e., decrease
n pump failure and severe cardiac arrhythmias).
A decrease in the occurrence of heart failure after BMC
herapy might be related to the contractile and antiremod-
ling action of BMCs in the infarcted myocardium. This
tudy has shown a broad spectrum of improved functional
ariables, including improved conditions (e.g., decrease in
ystolic wall stress), increased myocardial contractility (e.g.,
CF), enhanced ventricular power (as reflected, for example,
y LV power index and by ratio Psyst/ESV) and—as the
onsequence of these variables—an improvement of the overall
nd regional ventricular performance. Because these effects
re persistent over years, it is reasonable to assume that they
re the basis for the long-lasting antifailing property of
MC therapy in patients with AMI. BMC therapy seems
o exert structural effects in the sense that remodeling might
e prevented or delayed, thereby enabling the heart for
etter overall performance. The second main reason for the
ecrease in mortality in the BMC-treated patients refers to
ardiac arrhythmias. There is good evidence that an im-
aired LV function increases malignant ventricular arrhyth-
ias and predisposes for sudden cardiac death. Large
tudies concerning the spontaneous course of ischemic
ardiomyopathy demonstrate an incidence of 20% to 30%/
ear of sudden cardiac death induced by malignant ventric-
lar arrhythmias after AMI. All treated patients in this
tudy revealed no malignant arrhythmias, and there was
vidence for a decreased arrhythmogenic risk as shown by
he improvement of HRV and LP. It is likely that decreased
rrhythmogenic risk in BMC-treated patients obtains its
emodynamic equivalent by the BMC-induced antiremod-
ling properties, with improvement in LV function.
onclusions and Clinical Perspective
edical treatment or revascularization after AMI can improve
he function of viable or hibernating myocardium but cannot
estore necrotic myocardial tissue. Current therapy strategies
re limited in prevention and reversal of LV remodeling after
MI. Consequently, therapeutic regimens are desirable, which
lternatively or in addition to conventional therapy might
mprove ventricular performance and increase survival after
MI.
1The results of the present study demonstrate that BMC
herapy represents a novel and effective therapeutic proce-
ure for the repair of infarcted myocardium and offers a new
ossibility for the treatment after AMI. The long-term
urvival analysis shows that BMC therapy reduces mortality
n treated patients. In the long-term follow-up no side
ffects of BMC therapy were observed, demonstrating that
MC therapy is safe. Because of the relatively small sample
ize of the BALANCE study, further studies with greater
ample size are required to confirm the findings of the
resent study and to determine which cell biological and
olecular mechanisms are responsible for heart muscle
epair as well as to clarify which is the ideal mode of cell
reparation technique and application.
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